Related Experiment Video
Updated: Sep 29, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents
Abstract:
Increasing knowledge of the structure and function of the Epidermal Growth Factor Receptor (EGFR) subfamily of tyrosine kinases, and of their role in the initiation and progression of various cancers has led to the search for inhibitors of signaling molecules that may prove to be important in cancer therapy. The complex nature of EGFR biology allows for potential opportunities for EGFR inhibitors in a number of areas of cancer therapy, including proliferative, angiogenic, invasive, and metastatic aspects. Different approaches have been used to target either the extracellular ligand-binding domain of the EGFR or the intracellular tyrosine kinase region that results in interference with its signaling pathways that modulate cancer-promoting responses. Examples of these include a number of monoclonal antibodies, immunotoxins and ligand-binding cytotoxic agents that target the extracellular ligand binding region of EGFR, and small molecule inhibitors that target the intracellular kinase domain and act by interfering with ATP binding to the receptor. During the past 3 years, significant progress has been made towards the identification of new structural classes of small molecule inhibitors that show high potency and specificity towards EGFR. The search for new small molecules that inhibit kinases has included traditional approaches like the testing of natural products, random screening of chemical libraries, the use of classical structure-activity-relationship studies, and the incorporation of structure-based drug design and combinatorial chemistry techniques. There has been a significant improvement in the development of selective EGFR inhibitors with the use of a structure-based design approach employing a homology model of the EGFR kinase domain. Molecular modeling procedures have been used to generate novel molecules that are complementary in shape and electrostatics to the EGFR kinase domain topography. This review focuses on some examples of the successful use of this method.
Insights
Researchers are developing targeted cancer therapies by inhibiting the Epidermal Growth Factor Receptor (EGFR). Structure-based drug design is key to creating potent and specific EGFR inhibitors for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The Epidermal Growth Factor Receptor (EGFR) is crucial in cancer initiation and progression.
- EGFR signaling pathways regulate cancer proliferation, angiogenesis, invasion, and metastasis.
- Targeting EGFR offers therapeutic opportunities in various cancers.
Purpose of the Study:
- To review the development of EGFR inhibitors for cancer therapy.
- To highlight the role of structure-based drug design in creating selective inhibitors.
- To showcase successful applications of molecular modeling in EGFR inhibitor design.
Main Methods:
- Targeting extracellular ligand-binding domain and intracellular tyrosine kinase regions of EGFR.
- Utilizing monoclonal antibodies, immunotoxins, and small molecule inhibitors.
- Employing structure-based drug design with homology modeling and molecular modeling.
Main Results:
- Significant progress in identifying potent and specific small molecule EGFR inhibitors.
- Structure-based design has improved the development of selective EGFR inhibitors.
- Molecular modeling successfully generated novel molecules targeting the EGFR kinase domain.
Conclusions:
- EGFR inhibitors represent a promising avenue for cancer therapy.
- Structure-based drug design is a powerful approach for developing selective kinase inhibitors.
- Continued research in EGFR inhibitor development holds significant therapeutic potential.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Inhibition of Cdk Activity
